Triethanolamine salicylate is one of those ingredients that sits at the boundary between cosmetics and pharmaceuticals - depending on the market and the product positioning, the same molecule can be an OTC drug active ingredient, a cosmetic functional ingredient, or a sunscreen UV filter. Its dual identity as both a salt of triethanolamine (TEA) and a derivative of salicylic acid gives it a performance profile that neither parent compound possesses alone.
Despite monthly search volumes in the thousands and widespread use in topical analgesic creams sold in every pharmacy in North America and Europe, triethanolamine salicylate is poorly understood even by many cosmetic and pharmaceutical formulators who have never made it themselves. This article covers what it is, how it is made, what it does in different product types, how to formulate with it, and how it differs from using pure TEA or salicylic acid as separate ingredients. For TEA raw material specifications, see our Triethanolamine product page.
🧪 What Is Triethanolamine Salicylate?
Triethanolamine salicylate (TEA salicylate, INCI: Triethanolamine Salicylate, CAS 2174-16-5) is the salt formed when triethanolamine reacts with salicylic acid in an acid-base neutralisation reaction. TEA, a mild base, accepts a proton from salicylic acid, forming a triethanolamine cation and a salicylate anion that remain associated as an ionic salt:
N(CH₂CH₂OH)₃ + HOC₆H₄COOH → [HN(CH₂CH₂OH)₃]⁺ [OC₆H₄COO]⁻
Triethanolamine + Salicylic acid → Triethanolamine salicylate (ionic salt)
The resulting salt is a white to off-white crystalline solid or a colourless to pale yellow concentrated aqueous solution, depending on the form used commercially. It is fully water soluble at the concentrations used in pharmaceutical and cosmetic formulations - a key practical advantage over salicylic acid itself, which has limited water solubility (~2 g/L at 20 °C).
| INCI / INN Name | Triethanolamine Salicylate |
| CAS Number | 2174-16-5 |
| Molecular Formula | C₁₃H₂₁NO₆ (as free acid equivalent, MW 287.31) |
| Appearance | White crystalline solid or pale yellow aqueous solution |
| Water Solubility | Freely soluble (vs. 2 g/L for salicylic acid) |
| Salicylate content | ~47.8% w/w (as salicylic acid equivalent) |
| pH of 10% aqueous solution | ~6.5 – 7.5 |
| Primary regulatory category | OTC drug active (US); cosmetic ingredient (EU) |
⚗️ How Triethanolamine Salicylate Is Made
TEA salicylate can be produced by two routes: as a pre-formed salt (purchased as a raw material) or by in-situ salt formation during the formulation manufacturing process.
TEA salicylate is synthesised by dissolving equimolar quantities of salicylic acid and triethanolamine in water or a co-solvent, mixing at 40–60 °C until complete dissolution and salt formation, then spray-drying or crystallising to produce the solid form. The solid is then purchased as a finished raw material by formulators.
Many formulators - particularly those making cosmetic or muscle-rub products - prepare TEA salicylate in situ by separately adding salicylic acid and TEA to the formulation batch. The acid-base reaction occurs in the product itself, generating the salicylate salt in the finished formulation. The stoichiometry is: 1 mole salicylic acid (138.12 g) neutralised by 1 mole TEA (149.19 g).
When forming TEA salicylate in situ, use exactly 1.08 g of TEA per gram of salicylic acid (the 149.19/138.12 molar mass ratio). An excess of TEA will raise the formulation pH and leave free TEA that provides no salicylate activity. An excess of salicylic acid will lower the pH and leave free acid that may irritate skin. For analytical verification, measure the final formulation pH - a well-formed TEA salicylate system should sit at pH 6.5–7.5 in aqueous solution.
💊 What Triethanolamine Salicylate Does: Mechanisms and Benefits
The therapeutic and functional properties of TEA salicylate derive primarily from the salicylate anion - the active species that crosses the skin barrier and exerts pharmacological effects. TEA's contribution is primarily formulation chemistry: it solubilises the salicylate, adjusts pH to the optimal range for skin penetration, and contributes mild emulsification in cream systems.
🩺 Anti-inflammatory and Analgesic Activity
Salicylates are non-selective COX-1 and COX-2 inhibitors - they reduce prostaglandin synthesis by inhibiting cyclooxygenase enzymes, producing anti-inflammatory and analgesic effects. When delivered topically as TEA salicylate, the salicylate anion penetrates the stratum corneum and reaches the underlying dermis and musculature at therapeutically relevant concentrations. Topical salicylate therapy is effective for musculoskeletal pain, arthritis, and soft tissue injuries where systemic NSAIDs are not desired or tolerated.
☀️ UV-B Filtering (Sunscreen Function)
Salicylates absorb UV radiation in the UV-B range (280–320 nm), with maximum absorption around 305–310 nm. TEA salicylate is listed as an approved UV filter in sunscreen formulations in both the US (FDA Monograph, max 12%) and EU (Annex VI of EU Cosmetics Regulation, max 12%). Its water solubility makes it valuable in water-resistant sunscreen formulations where an aqueous-phase UV filter is needed alongside oil-phase UV-B and UV-A filters.
As a UV filter, TEA salicylate provides modest SPF contribution - typically 2–4 SPF units per 1% concentration in a standard emulsion - and is used primarily as a supporting UV-B filter alongside more potent filters such as octinoxate, homosalate, or avobenzone rather than as a primary sunscreen active.
🧴 Keratolytic Activity at Higher Concentrations
At higher concentrations (above ~2% salicylic acid equivalent), the salicylate component provides keratolytic (skin-softening) activity by disrupting the desmosomes holding corneocytes together in the stratum corneum. This makes TEA salicylate useful in formulations for callus softening, corn treatment, and psoriasis management - applications where controlled exfoliation of the thickened keratin layer is the therapeutic goal. At the lower concentrations used in analgesic and sunscreen applications (0.5–12% as TEA salicylate), keratolytic effects are minimal.
🔬 Why the Salt Form Outperforms Free Salicylic Acid
TEA salicylate: freely soluble. Salicylic acid: 2 g/L at 20 °C. The salt form enables concentrations of 5–15% in aqueous systems that are impossible with the free acid, dramatically expanding formulation possibilities for water-based products.
Free salicylic acid at therapeutic concentrations causes skin irritation, particularly in sensitive individuals. The buffered pH of the TEA salt system (pH ~7.0) significantly reduces irritation while maintaining therapeutic efficacy - the salicylate anion penetrates less rapidly than the undissociated acid, but achieves comparable steady-state tissue concentrations.
Salicylic acid is susceptible to ester hydrolysis and oxidation in aqueous emulsions, particularly at low pH. The TEA salt form is chemically more stable in aqueous media, producing products with acceptable shelf life (24+ months) when stored under normal conditions.
Free salicylic acid is incompatible with iron salts (produces coloured complexes), proteins (precipitates), and strongly alkaline ingredients. The TEA salt is compatible with a wider range of formulation components, simplifying product design for multi-active formulations.
🏥 Product Applications
1 - Topical Analgesic Creams and Gels (OTC Drug)
This is the largest commercial application of TEA salicylate by value. Over-the-counter topical analgesic products for arthritis, muscle pain, back pain, and sports injuries commonly use TEA salicylate as the active ingredient at concentrations of 10–15% in a cream or gel base. Well-known product categories in this space include arthritis rubs, sports creams, and analgesic liniments.
In the US, topical OTC analgesics containing salicylates are regulated under the FDA's OTC Drug Monograph system (21 CFR Part 348). TEA salicylate is specifically listed as a permitted counterirritant and external analgesic active ingredient at 10–15% concentration. Products must include the required OTC drug labelling elements including directions for use, warnings, and active ingredient declaration.
2 - Sunscreen Formulations
TEA salicylate is approved as a UV-B filter in sunscreen products in both the US (max 12%, FDA Monograph) and EU (max 12%, Annex VI). Its water solubility and neutral pH make it an attractive aqueous-phase UV filter that can be incorporated into the water phase of an emulsion, avoiding the need to dissolve all UV filters in the oil phase.
In sunscreen formulations, TEA salicylate is typically used as a secondary UV-B filter in combination with higher-SPF-contribution oil-soluble filters. A standard combination in European sunscreens might be: 5% TEA salicylate (water phase) + 7.5% octinoxate (oil phase) + 3% avobenzone (oil phase) + UV-A filter, achieving a broad-spectrum protection profile.
3 - Anti-Acne and Keratolytic Treatments
At concentrations of 0.5–2% (as salicylic acid equivalent), TEA salicylate can be used in anti-acne formulations - face washes, toners, and treatment serums. The keratolytic action helps clear pore-blocking dead skin cells, and the antibacterial properties of salicylate reduce C. acnes colonisation. The TEA salt form is preferred over free salicylic acid in aqueous or gel-based anti-acne products because it enables higher effective concentrations at skin-compatible pH.
4 - Foot Care and Callus Softeners
TEA salicylate at 2–5% (as salicylic acid equivalent) is used in foot care formulations - heel creams, callus softeners, and corn treatments - to soften thickened hyperkeratotic skin. The buffered pH of the TEA salt form reduces the risk of skin irritation during prolonged foot soak applications compared to free salicylic acid at equivalent concentrations.
🔬 Formulation Guide
Typical Analgesic Cream Formulation Approach
Salicylic acid's limited water solubility at ambient temperature is overcome by heating. Dissolve the salicylic acid in approximately 30–40% of the total water quantity at 65 °C before adding other water-phase ingredients. Do not add TEA yet - adding base to undissolved salicylic acid crystals can produce a heterogeneous reaction mixture with inconsistent salt formation.
Add the calculated TEA quantity (1.08 g TEA per g salicylic acid for equimolar neutralisation) slowly to the hot salicylic acid solution with stirring. The solution will clear immediately on salt formation. Verify pH - target 6.8–7.2 for a neutral analgesic system. Adjust with additional salicylic acid (to lower pH) or TEA (to raise pH) in small increments if needed. Avoid exceeding pH 7.5, which indicates excess free TEA.
For cream formulations, prepare a standard O/W emulsion base using your chosen emulsifier system (cetearyl alcohol/polysorbate 60, or stearic acid/additional TEA for TEA-stearate emulsification). Keep the oil phase at 70–75 °C. The TEA salicylate solution is added to the water phase after emulsification and cooling - not before - to avoid any interference of the salicylate anion with the emulsification process.
Once the emulsion base has cooled below 45 °C, blend in the TEA salicylate solution with slow, careful mixing. High shear at this stage can destabilise the emulsion. Re-check pH after incorporation - some emulsion components are slightly acidic and may lower the pH below the target range. Adjust with a small quantity of TEA (not salicylic acid) to bring back to pH 6.8–7.2.
Salicylate ion has mild antibacterial activity, which contributes to the overall preservation of the formulation, but is not sufficient on its own at typical use concentrations. A non-nitrosating preservative system compatible with TEA is required: phenoxyethanol 0.5–1%, ethylhexylglycerin 0.1–0.3%, or sodium benzoate/potassium sorbate at pH ≤6.5. Note that sodium benzoate is less effective above pH 6.0 - if your formulation targets pH 7.0, phenoxyethanol-based preservation is more reliable.
Compatibility Considerations
| Ingredient / Category | Compatibility with TEA Salicylate | Note |
|---|---|---|
| Carbomer gels | ✅ Excellent | TEA neutralises carbomer; salicylate does not interfere with gelation |
| Iron-containing ingredients (e.g., iron oxides) | ⛔ Incompatible | Salicylate chelates iron, producing purple-brown discolouration |
| Cationic surfactants (e.g., BTAC, cetrimonium) | ⚠️ Potential incompatibility | Anionic salicylate can form insoluble complexes with quaternary ammonium cations - test before formulating |
| Proteins and hydrolysed proteins | ⚠️ Caution | Salicylate can bind to protein, potentially reducing both salicylate bioavailability and protein functionality |
| Niacinamide | ✅ Compatible | No known interaction at use concentrations; beneficial combination for acne formulations |
| Other oil-soluble UV filters | ✅ Compatible | TEA salicylate (water phase) combines well with octinoxate, avobenzone, homosalate (oil phase) in sunscreen formulations |
| Nitrosating preservatives (bronopol, DMDM hydantoin) | ⛔ Prohibited | TEA component can participate in nitrosamine formation; use non-nitrosating preservation systems |
🌍 Regulatory Status Across Markets
TEA salicylate occupies different regulatory categories in different markets - a nuance that has direct implications for product registration, labelling, and claims.
In the EU, UK, Australia, and most Asian markets, a product containing TEA salicylate cannot make therapeutic claims (e.g., "relieves arthritis pain," "reduces muscle inflammation") and remain classified as a cosmetic. Making such claims triggers classification as a medicinal product, which requires a full pharmaceutical registration - a substantially different and more demanding regulatory pathway. Products positioned as cosmetics with TEA salicylate must restrict claims to descriptive or cosmetic language. In the US, the OTC drug monograph system provides a pathway for therapeutic claims without full NDA, but still requires OTC labelling compliance.
❓ Frequently Asked Questions
📝 Summary
Triethanolamine salicylate sits at a productive intersection of chemistry, pharmacy, and cosmetic formulation. The combination of TEA's base chemistry with salicylic acid's anti-inflammatory and UV-absorbing properties creates an ingredient that outperforms either component used alone in the applications where it is most valuable: topical analgesics, sunscreen UV filters, and mild keratolytic treatments.
Its regulatory status - OTC drug in the US, cosmetic UV filter and functional ingredient in the EU - means that formulators working across markets need to make deliberate decisions about product classification and claims before finalising formulations. The in-situ preparation route using cosmetic- or pharmaceutical-grade TEA and salicylic acid is cost-effective and well-controlled when stoichiometry and pH management are properly executed. The compatibility considerations - particularly the incompatibility with iron-containing ingredients and nitrosating preservatives - are manageable with standard formulation diligence.
For buyers of TEA as a raw material for TEA salicylate production, the key specification requirement is pharmaceutical- or cosmetic-grade TEA-99 with certified low DEA content and full documentation chain. This ensures the finished TEA salicylate product meets regulatory requirements in all target markets without the need for reformulation or re-documentation later in the product lifecycle.
Sinolook Chemical supplies TEA-99 cosmetic grade (DEA ≤0.5%, APHA ≤50, nitrosamine-free CoA) suitable for in-situ TEA salicylate preparation in sunscreen and personal care formulations. Pharmaceutical USP/Ph.Eur. grade available on request for OTC drug manufacturing. Available in 25 kg, 200 kg drum, and 1,000 kg IBC packaging.
